Menu Search
Equities

Aptorum Group Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
A1V0:MUN

Aptorum Group Ltd

Actions
  • Price (EUR)3.00
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta-0.0753
Data delayed at least 15 minutes, as of Feb 28 2023 09:07 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Aptorum Group Limited is a United Kingdom-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated2010
  • Employees1.00
  • Location
    Aptorum Group Ltd17 Hanover SquareLONDON W1S 1BNUnited KingdomGBR
  • Phone+44 208 092 9299
  • Fax+44 203 928 8277
  • Websitehttps://www.aptorumgroup.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.